<%@ LANGUAGE="VBSCRIPT" %> The Mouth and Lupus

LUPUS: A GP Guide to Diagnosis

The Mouth and Lupus

Introduction

The mouth can be affected by lupus erythematosus in a variety of ways but the most frequently occurring conditions are mucosal patches which are found in 10-25% of cases and xerostomia, which develops in up to 30% of sufferers. The mucosal lesions usually produce minimal symptoms whilst a lack of saliva causes a number of significant problems.

Mucosal patches

The mucosal lesions of lupus range from ulcerative or erythematous patches to white keratotic plaques (Figure 1). The clinical appearance is similar to both lichen planus and lichenoid reactions. The buccal mucosal is the site most frequently affected although any area of the mouth may be involved. The mucosal lesions are often painless but some patients may complain of pain. Topical steroid mouthwash, in the form of either betamethasone (0.5mg, betnesol) or prednisolone (5mg, prednesol), held in the mouth for five minutes three times daily will resolve any discomfort. The possibility that intra-oral changes represent a lichenoid reaction rather than lupus itself must always be considered since such mucosal lesions are seen relatively frequently with the use of the nonsteroidal anti-inflammatory drugs that patients with lupus may be taking. If the onset of any oral symptoms coincides with the provision of systemic drug therapy then it may be necessary to consider an alternative medication.

Figure 1. White keratotic patch of lupus in the left buccal mucosa.
Figure 1. White keratotic patch of lupus in the left buccal mucosa.

Xerostomia (Dry mouth)

Saliva is produced by three pairs of major glands (parotid, submandibular and sublingual) and numerous minor glands scattered throughout the mouth. In health, the salivary glands produce approximately 0.75 litre of saliva in 24 hours. Almost a third of lupus patients suffer from a significant reduction in the production of saliva which causes oral symptoms (Table 1) and signs (Table 2). In addition to being dry, the oral mucosa becomes erythematous and the tongue may appear lobulated (Figure 2).

Table 1 - Symptoms of dry mouth
Difficulty in talking
Difficulty in swallowing
Loss of taste
Altered taste
Generalised oral discomfort
Difficulty with dentures
Discomfort at the angles of the mouth

Table 2 - Signs of dry mouth
Absence of saliva or frothy saliva
Erythematous mucosa
Lobulated tongue
Dental caries, particularly at the cervical margins
Fracture and loss of dental restorations
Erythematous and pseudomembranous candidosis
Angular cheilitis

Figure 2. Lobulated appearance of the tongue as a result of xerostomia.
Figure 2. Lobulated appearance of the tongue as a result of xerostomia.

Investigation of xerostomia

The presence of a dry mouth can be crudely assessed by either simply looking in the patient's mouth to see if saliva is pooling behind the lower incisors or by placing the face of a dental mirror against the buccal mucosa (the mirror will stick to the mucosa if salivary levels are reduced).
In addition to these simple tests, a number of special investigations have been developed to detect reduced salivary production. Such special techniques include measurement of salivary flow rates, sialography, scintiscanning, serology and labial gland biopsy. The extent to which each of these tests is used will depend on an individual patient's history and the availability of the required facilities.

Treatment of xerostomia

Treatment of dry mouth must not only involve attempts to replace the lack of saliva by the use of salivary substitutes or stimulants but should also include measures to minimise secondary problems, in particular dental caries (Figure 3).

Figure 3. Fracture of dental restorations and caries due to xerostomia.
Figure 3. Fracture of dental restorations and caries due to xerostomia.

Infection

Approximately 40% of the adult population harbour candida in their mouths as part of the commensal oral flora. Reduced salivary flow can lead to an increase in the numbers of candida resulting in opportunistic oral candidoses. The clinical presentation may be either white pseudomembranes (thrush) or erythematous atrophic areas of mucosa. Candidal infections are particularly frequent if the patient wears dentures. Topical antifungal agents are of little or no benefit in the management of oral candidosis and, therefore, it is preferable to provide a seven-day course of systemic fluconazole (50mg daily). The need for denture hygiene should be stressed if there is evidence of candidal infection. Full dentures should be placed in a dilute solution of hypochlorite at night for approximately three weeks. Partial dentures with metal components should be placed in chlorhexidine.

Opportunistic bacterial infection may develop in the salivary glands, particularly the parotid glands, due to reduced flow of saliva down the excretory duct. Acute infection presents as a painful swelling of the affected gland accompanied by a discharge of pus at the main duct orifice. Oral amoxycillin is the antibiotic therapy of choice whilst erythromycin should be used in patients with a hypersensitivity to penicillins.

Dr. Michael A. O. Lewis
Reader and Consultant in Oral Medicine
Dental School
University of Wales College of Medicine
Heath Park, Cardiff, CF44XY